EnteroMedics (NSDQ:ETRM) today released a real-world assessment of weight loss data from patients using its Maestro vBloc therapy device and associated programs, touting between 9% and 10% total weight loss at 6 and 9 months, respectively. St. Paul, Minn.-based EnteroMedic’s Maestro device is an implantable neurostimulation device designed to intermittently block the vagus nerves using high-frequency, low-energy […]
EnteroMedics Inc.
LimFlow taps Rose for CEO | Personnel Moves
LimFlow taps ex-Direct Flow GM Rose as CEO LimFlow said this week that it tapped former Direct Flow Medical VP and GM Daniel Rose as its new chief executive, with former co-founder & CEO Timothy Lenihan transitioning to chief technology officer. LimFlow is developing a device to create percutaneous venous arterialization in the foot to treat end-stage critical limb […]
EnteroMedics shareholders reject reverse split, annual meeting canceled
EnteroMedics (NSDQ:ETRM) said yesterday it cancelled a special meeting of stockholders it had scheduled to vote on increasing stock numbers and initiating a reverse stock split after a lack of support from shareholders. The company sought to increase the number of shares of common stock to 650 million in its 1st proposition, and was looking […]
Avedro taps Visiogen founder Zadno for CEO | Personnel Moves Sept. 9 2016
Avedro taps Visiogen founder Zadno for CEO Avedro said it named the founder, president of Abbott (NYSE:ABT) acquisition Visiogen, Reza Zadno, to be its new CEO. Zadno replaces CFO/COO Brian Roberts, the former CFO at Insulet (NSDQ:PODD), who stepped in on an interim basis when David Muller bowed out shortly after Avedro closed a $32 million […]
FDA warns Oscor on process control records
The FDA last month warned contract manufacturer Oscor on its methods for documenting process controls for the catheters and neurostimulation leads it makes, after inspections in February and March turned up a trio of violations. The federal safety watchdog said it inspected Oscor’s plant in Palm Harbor, Fla., where it makes the Adelante Magnum introducer catheter and lead […]
EnteroMedics Maestro neurostim device used as ‘rescue’ therapy after failed surgeries
EnteroMedics (NSDQ:ETRM) said today that its Maestro device was used a pair of patients whose gastric sleeve procedures failed to bring the hoped-for weight loss and reduction in diabetes symptoms. St. Paul, Minn.-based EnteroMedics calls the Maestro therapy “vBloc,” as it’s designed to stimulate the vagus nerve to control feelings of hunger and satiety. The […]
EnteroMedics closes $6m convertible debt tranche
EnteroMedics (NSDQ:ETRM) said today it closed the 3rd tranche in a $25 million offering of Senior Amoritizing Convertible Notes, bringing in $6.3 million for the company. The original securities offering consisted of 3 tranches, but has been amended to allow for a 4th tranche of $6.25 million which must be drawn or waived by August […]
EnteroMedics inks deal with VA distributor for Maestro anti-obesity device
EnteroMedics (NSDQ:ETRM) said today that it signed a distribution deal for its Maestro weight-loss device with Academy Medical, an orthopedic implant and wound care supplier to the U.S. Veterans Affairs Dept. and the U.S. Defense Dept. The Maestro device is an implantable neurostimulation device designed to intermittently block the vagus nerves using high-frequency, low-energy impulses. The therapy, which St. […]
EnteroMedics touts study showing improved weight loss in moderate obesity patients
EnteroMedics (NSDQ:ETRM) today released data from the ReCharge study of its vBloc Neurometabolic Therapy in patients with moderate obesity, touting 74% greater weight loss with vBloc therapy compared to a sham control. Full results from the St. Paul, Minn.-based company’s trial were published in the journal Obesity Surgery. “Results observed in the moderately obese population provide strong […]
Enteromedics lands $11M in 2nd convertible notes tranche
EnteroMedics (NSDQ:ETRM) said today it closed the 2nd tranche of the $25 million senior amortizing convertible notes offering it announced last November, bringing in $11 million. At the initial closing in November the company received $1.5 million, with a 3rd tranche of $12.5 million scheduled in 45 days, the St. Paul, Minn.-based company said. Enteromedics […]
Ivenix taps ex-GI Dynamics chief Randle for CEO | Personnel Moves
Ivenix said in named former GI Dynamics (ASX:GID) chief Stuart Randle to be its new CEO. Randle departed GI Dynamics in August 2014, after 10 years with the bariatric device maker. Amesbury, Mass.-based Ivenix, which raised $42 million last September, is developing an infusion management system for hospitals that will combine an information technology interface […]